Wang Rongrong, Li Ning, Zhang Yinhui, Ran Yuqin, Pu Jielin
Pathology and Physiology Research Center, and Center for Arrhythmia Diagnosis and Treatment, Cardiovascular Institute and Fu Wai Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, China.
Intern Med. 2011;50(17):1789-95. doi: 10.2169/internalmedicine.50.5129. Epub 2011 Sep 1.
Recent studies have revealed that microRNAs (miRNAs) are involved in the regulation of cardiac development, physiologic, and pathologic processes via post-transcriptional control of gene expression. The stable circulating miRNAs offer unique opportunities for the early diagnosis of several diseases. In this study, we examined the circulating miR-133 and miR-328 levels from patients with acute myocardial infarction (AMI).
Twenty-eight control subjects and fifty-one consecutive AMI patients were enrolled. The plasma and whole blood samples from AMI patients were obtained within 24 hours (n=51) and 7 days (n=6) after the onset of AMI symptoms. The circulating miR-133 and miR-328 levels were analyzed using quantitative real-time PCR.
The miR-133 levels in plasma from AMI patients exhibited a 4.4-fold increase compared with control subjects (p=0.006). Moreover, the increased miR-133 levels in whole blood were comparable with those in plasma samples. In contrast, the miR-328 levels in plasma and whole blood of AMI patients were markedly increased by 10.9-fold and 16.1-fold, respectively, compared to those in control subjects (p=0.033 and p<0.001). The elevated circulating miR-133 and miR-328 levels were recovered to the control levels at 7 days after AMI. In addition, there was a correlation between circulating miR-133 or miR-328 levels and cardiac troponin I. Furthermore, circulating miR-133 or miR-328 showed no significant changes in AMI patients with tachyarrhythmia (n=24) or bradyarrhythmia (n=26) compared to those in patients without arrhythmias. Receiver operating characteristic curve analysis revealed that the areas under the curve of miR-133 or miR-328 in plasma and whole blood were 0.890, 0.702 and 0.810, 0.872, respectively (all p<0.05).
The miR-133 and miR-328 levels in plasma and whole blood in AMI patients were increased compared to those in control subjects. These miRNAs may represent novel biomarkers of AMI.
最近的研究表明，微小RNA（miRNA）通过对基因表达的转录后控制参与心脏发育、生理和病理过程的调节。稳定循环的miRNA为多种疾病的早期诊断提供了独特的机会。在本研究中，我们检测了急性心肌梗死（AMI）患者循环中miR-133和miR-328的水平。
纳入28名对照受试者和51名连续的AMI患者。在AMI症状发作后24小时（n=51）和7天（n=6）采集AMI患者的血浆和全血样本。使用定量实时PCR分析循环中miR-133和miR-328的水平。
AMI患者血浆中miR-133水平与对照受试者相比升高了4.4倍（p=0.006）。此外，全血中miR-133水平的升高与血浆样本中的升高相当。相比之下，AMI患者血浆和全血中的miR-328水平分别比对照受试者显著升高了10.9倍和16.1倍（p=0.033和p<0.001）。AMI后7天，循环中升高的miR-133和miR-328水平恢复到对照水平。此外，循环中miR-133或miR-328水平与心肌肌钙蛋白I之间存在相关性。此外，与无心律失常的患者相比，AMI合并快速心律失常（n=24）或缓慢性心律失常（n=26）的患者循环中miR-133或miR-328无显著变化。受试者工作特征曲线分析显示，血浆和全血中miR-133或miR-328的曲线下面积分别为0.890、0.702和0.810、0.872（均p<0.05）。
与对照受试者相比，AMI患者血浆和全血中的miR-133和miR-328水平升高。这些miRNA可能代表AMI的新型生物标志物。
